Glaxo Board and Activist Hedge Fund Bluebell Spar in New Letters
(Bloomberg) -- GlaxoSmithKline Plc's board hit back at Bluebell Capital Partners after the activist hedge fund called for the removal of both the chairman and chief executive officer.
GSK Chairman Jonathan Symonds wrote to Bluebell's partners on Wednesday, saying the drugmaker was “disappointed” in their account of an investor meeting aimed at updating investors on progress toward spinning off the consumer unit. In the letter seen by Bloomberg, Symonds said remarks made at the forum were taken out of context, and he backed steps CEO Emma Walmsley and her team have taken to improve the company's performance.
Bluebell hit back in its own letter Thursday, calling GSK's version of events “simply untrue” and reiterating demands for a “radical reshuffle” of the board. Last month, the firm invested about 10 million pounds ($14 million) in GSK, a company with a market capitalization of more than 70 billion pounds.
“We have said all we are going to say on the matter,” a GSK spokesman said.
©2021 Bloomberg L.P.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.
-
It's Time To Take The GST Council's Bet On Trust Global
Payment records can prove India's services exports, and clear, proportionate rules can bring foreign digital sellers into the tax net.
-
Opinion | India at 38: From Innovation Overperformer to Innovation Powerhouse
India now has 453 VC-backed deep science startups, 18 of them late-stage, after 117 percent growth since 2020. Laurus Labs, at USD 9.3 billion, is the most valuable deep science company in any middle-income economy outside China.
-
Navigating Energy Crossroads: S Jaishankar's Call For Diversified Supply Chains At G20 Ministerial Meeting
As geopolitical fault lines continue to test maritime trade routes and commodity flows, Jaishankar's message remains pertinent: true economic resilience requires open markets, protected transit lines, and a genuine commitment to multilateral cooperation rather than coercion.
-
Indians Are Travelling, But Not Every Journey Is A Holiday | The Week In Whys
Pilgrims, patients and working women are the real travellers, and the system hasn't quite caught up with them.
-
Getting To Work Costs Women More | The Reason Why
It is not just about women paying more than men. It is about women paying much more in cities than in villages.
-
AI Bias In Investing Cannot Be Eliminated, But It Can Be Governed
Framing is a particularly important example as identical financial information presented in terms of gains rather than losses can lead an LLM to reach a different assessment.
